ArticleBMC infectious diseases2026
Hepatitis B virus prevalence, susceptibility and care engagement among vulnerable migrant populations in Rome.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHepatitis B virus (HBV) remains a leading cause of morbidity and liver-related mortality globally. Vulnerable migrant populations often experience challenges with accessing testing, vaccination and care, both before and after arrival.
methodsAsylum seekers and undocumented migrants hosted in six reception facilities in metropolitan Rome were prospectively offered screening for hepatitis B surface antigen (HBsAg), surface antibodies (anti-HBs) and core antibodies (anti-HBc). Individuals with HBsAg positivity were assisted in accessing a specialist referral service, with support available throughout the screen-and-link pathway to reduce administrative, linguistic and logistic barriers.
resultsBetween February 2024 and August 2025, 435 individuals from 38 countries underwent screening (median age 28 years; 86.7% male). Most (273; 62.8%) were non-immune (HBsAg/anti-HBc/anti-HBs negative), 88 (20.2%) had prior infection (HBsAg negative/anti-HBc positive, usually with anti-HBs), and 51 (11.7%) had vaccine-induced immunity (anti-HBs positive only). HBsAg was detected in 23 (5.3%; 95% CI 3.6-7.8), including 16/149 (10.7%) participants from the African region and 7/160 (4.4%) from South-East Asia (all from Bangladesh); none had hepatitis delta, hepatitis C or HIV coinfection. Overall, 20/23 (87.0%) were successfully engaged in care; 5/20 (25%) met immediate treatment indications based on virological, biochemical and/or liver fibrosis criteria.
conclusionsThis study highlights the dual public health challenge of chronic HBV infection and lack of HBV immunity among asylum seekers and undocumented migrants in Rome. The initially high linkage to care demonstrates the effectiveness of integrated screen-and-link approaches. Strengthened HBV testing, vaccination and care pathways should be proactively embedded within health services for vulnerable migrant populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.